ZVRA
Zevra Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.40
−1.12%0
Insider buys (3m)
3
Insider sells (3m)
-$1.1M
Net value (3m)
+18.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 17, 2026 | Thompson Rahsaan · officer: Chief Legal & Compliance | Sale | 42,666 | $11 |
| Aug 12, 2026 | Watton Corey Michael · director | Sale | 12,300 | $11 |
| Aug 12, 2026 | Watton Corey Michael · director | M-Exempt | 12,300 | $4.97 |
| Jun 23, 2026 | Thompson Rahsaan · officer: Chief Legal & Compliance | M-Exempt | 66,667 | $0.00 |
| Jun 23, 2026 | Thompson Rahsaan · officer: Chief Legal & Compliance | Sale | 34,557 | $13 |
| Jun 18, 2026 | FAVORITO TAMARA A · director | A-Award | 30,000 | $11 |
| Jun 18, 2026 | Anderson Thomas · director | A-Award | 30,000 | $11 |
| Jun 18, 2026 | Calder Douglas W · director | A-Award | 30,000 | $11 |
| Jun 18, 2026 | Watton Corey Michael · director | A-Award | 30,000 | $11 |
| Jun 18, 2026 | Secor Alicia · director | A-Award | 30,000 | $11 |
| Jun 18, 2026 | Shih Alvin · director | A-Award | 30,000 | $11 |
| May 29, 2026 | Sangiovanni Timothy J. · officer: SVP, Finance & Corp Controller | A-Award | 40,000 | $11 |
| May 29, 2026 | Sangiovanni Timothy J. · officer: SVP, Finance & Corp Controller | A-Award | 20,000 | $0.00 |
| May 13, 2026 | Thompson Rahsaan · officer: Chief Legal & Compliance | Sale | 1,794 | $11 |
| Mar 26, 2026 | Bode John B · director | M-Exempt | 39,200 | $4.97 |
| Mar 19, 2026 | Renz Justin A · officer: CFO | A-Award | 300,000 | $9.55 |
| Feb 10, 2026 | McFarlane Neil F. · director, officer: President and CEO | M-Exempt | 37,500 | $0.00 |
| Feb 10, 2026 | McFarlane Neil F. · director, officer: President and CEO | Sale | 14,625 | $8.56 |
| Feb 4, 2026 | Sangiovanni Timothy J. · officer: SVP, Finance & Corp Controller | Sale | 3,000 | $9.18 |
| Feb 4, 2026 | Schafer Joshua · officer: CCO | Sale | 10,500 | $9.19 |
| Feb 2, 2026 | Quartel Adrian W · officer: Chief Medical Officer | A-Award | 37,500 | $0.00 |
| Feb 2, 2026 | Sangiovanni Timothy J. · officer: SVP, Finance & Corp Controller | M-Exempt | 11,666 | $0.00 |
| Feb 2, 2026 | Sangiovanni Timothy J. · officer: SVP, Finance & Corp Controller | M-Exempt | 6,333 | $0.00 |
| Feb 2, 2026 | Sangiovanni Timothy J. · officer: SVP, Finance & Corp Controller | Sale | 1,750 | $8.82 |
| Feb 2, 2026 | Thompson Rahsaan · officer, other: Chief Legal & Compliance | A-Award | 75,000 | $8.86 |
| Feb 2, 2026 | Thompson Rahsaan · officer, other: Chief Legal & Compliance | M-Exempt | 11,333 | $0.00 |
| Feb 2, 2026 | Thompson Rahsaan · officer, other: Chief Legal & Compliance | Sale | 4,080 | $8.83 |
| Feb 2, 2026 | Thompson Rahsaan · officer, other: Chief Legal & Compliance | A-Award | 37,500 | $0.00 |
| Feb 2, 2026 | Quartel Adrian W · officer: Chief Medical Officer | A-Award | 75,000 | $8.86 |
| Feb 2, 2026 | Quartel Adrian W · officer: Chief Medical Officer | M-Exempt | 11,333 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 49Increased 115Reduced 97Sold out 17
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 5,108,871 | Aug 7, 2026 |
| FMR LLC | Increased | 4,915,717 | Aug 13, 2026 |
| Woodline Partners LP | Increased | 4,785,771 | Aug 14, 2026 |
| BLACKROCK, INC. | Reduced | 4,456,476 | May 13, 2026 |
| WOODLINE PARTNERS LP | Increased | 3,450,943 | May 15, 2026 |
| FMR LLC | Increased | 3,211,877 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,638,910 | Aug 13, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Increased | 2,521,936 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,469,328 | May 15, 2026 |
| CAPTION MANAGEMENT, LLC | Reduced | 2,353,136 | May 15, 2026 |
| Caption Management, LLC | Reduced | 2,222,800 | Aug 14, 2026 |
| Nantahala Capital Management, LLC | Reduced | 1,797,476 | Aug 19, 2026 |
| STATE STREET CORP | Increased | 1,681,999 | Aug 7, 2026 |
| STATE STREET CORP | Increased | 1,561,569 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 1,540,936 | Aug 12, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 17, 2026